Market opportunity analysis for HER2 targeted cell therapy.

Precision medicine is showing great promise in the fight against cancer by selectively targeting hallmarks of cancer cells to spare normal ones. One such hallmark of cancer is the overexpression of the HER2 protein in many different types of cancer.
At Modulari-T we have developed a way to program the immune system to recognize and kill cancer cells which we call MARC cells by sensing the overexpression of HER2.
This project aims to find the optimal indication for a HER2-directed cell therapy. A thorough analysis of HER2 overexpressing cancer incidence, the current standard of care for secondary line treatment (refractory or relapsed cancer) and the patient population profile will be used to analyze the market opportunity for the different indications that the therapy could be applied to.

Faculty Supervisor:

Étienne Gagnon

Student:

Partner:

Modulari-T Bioscience

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Université de Montréal

Program: